Patents by Inventor Izumi Kumagai

Izumi Kumagai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170274072
    Abstract: To provide bispecific antibodies and highly functional bispecific antibodies, which are produced by using a new anti-human EGF receptor 1 (Her 1) antibody different from the antibody 528. A bispecific antibody, comprising a variable region of the light chain (2L: SEQ ID NO:2) and a variable region of the heavy chain (2H: SEQ ID NO:4) of an anti-human EGF receptor 1 antibody 225, and a humanized variable region of the light chain (OL: SEQ ID NO:6) and a humanized variable region of the heavy chain (OH: SEQ ID NO:8) of an anti-CD3 antibody OKT, and the like.
    Type: Application
    Filed: February 25, 2015
    Publication date: September 28, 2017
    Applicant: TOHOKU UNIVERSITY
    Inventors: Izumi KUMAGAI, Ryutaro ASANO, Mitsuo UMETSU
  • Publication number: 20170183410
    Abstract: To provide a high-functional bispecific antibody, especially LH-type bispecific antibody that has further improved its function while maintaining the excellent cytotoxicity such as anti-tumor activity. A bispecific antibody for human EGF receptor 1 and CD3, comprising a variable region comprising a humanized variable region of the light chain (5L: SEQ ID NO:2) and a humanized variable region of the heavy chain (5H: SEQ ID NO:4) of an anti-human EGF receptor 1 antibody 528, and a humanized variable region of the light chain (OL: SEQ ID NO:6) and of a humanized variable region of the heavy chain (OH: SEQ ID NO:8) of an anti-CD3 antibody OKT; a hinge region; and an Fc region, characterized by that the Fc region is originated from human IgG2 sub-class.
    Type: Application
    Filed: February 25, 2015
    Publication date: June 29, 2017
    Applicant: TOHOKU UNIVERSITY
    Inventors: Izumi KUMAGAI, Ryutaro ASANO, Mitsuo UMETSU
  • Publication number: 20160115233
    Abstract: [Problem] The purpose of the present invention is to provide a bispecific antibody that is structurally stable, and can show alone a sufficient effect without the co-administration of activated lymphocyte (T-LAK). [Solution] The present invention is therefore related to a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3; and having one of the following structures (i)-(vi) in claim 1, wherein the 5H, 5L, OH and OL have an amino acid sequence represented by SEQ ID Nos 25, 26, 27 and 28, respectively.
    Type: Application
    Filed: January 8, 2016
    Publication date: April 28, 2016
    Applicant: TOHOKU UNIVERSITY
    Inventors: Izumi Kumagai, Ryutaro Asano
  • Patent number: 9315584
    Abstract: Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (LH-diabody type bispecific antibody) characterized in that an L-chain is located in the N-terminal side in each polypeptide (LH type); a humanized high-functional bispecific antibody which contains said LH diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule.
    Type: Grant
    Filed: January 4, 2010
    Date of Patent: April 19, 2016
    Assignee: TOHOKU UNIVERSITY
    Inventors: Izumi Kumagai, Ryutaro Asano, Mitsuo Umetsu
  • Patent number: 9315578
    Abstract: [Problem] The purpose of the present invention is to provide a bispecific antibody that is structurally stable, and can show alone a sufficient effect without the co-administration of activated lymphocyte (T-LAK). [Solution] The present invention is therefore related to a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3; and having one of the following structures (i)-(vi) in Claim 1, wherein the 5H, 5L, OH and OL have an amino acid sequence represented by SEQ ID Nos 25, 26, 27 and 28, respectively.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: April 19, 2016
    Assignee: TOHOKU UNIVERISTY
    Inventors: Izumi Kumagai, Ryutaro Asano
  • Publication number: 20150322156
    Abstract: The purpose of the present invention is to provide fragments of humanized anti-EGFR antibody substituted-lysine light-chain or heavy-chain variable regions, and single-chain antibodies, etc, comprising the same, having sufficient binding activity (affinity) with target cells, and having the ability to undergo various site-specific and uniform chemical modifications. The present invention pertains to a humanized variable region on the light-chain or heavy-chain of antibody 528 against human epidermal cell growth factor receptor 1 (Her-1), said variable region comprising the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4, wherein fragments of humanized anti-EGFR antibody lysine-substituted light-chain variable regions are formed by substituting a different amino acid for all of the lysine residues, or all of the lysine residues except for the lysine residue(s) of one specified moiety.
    Type: Application
    Filed: July 27, 2015
    Publication date: November 12, 2015
    Applicant: TOHOKU UNIVERSITY
    Inventors: Izumi KUMAGAI, Takeshi NAKANISHI, Hideaki SANADA, Ryutaro ASANO, Mitsuo UMETSU
  • Patent number: 9139650
    Abstract: The purpose of the present invention is to provide fragments of humanized anti-EGFR antibody substituted-lysine light-chain or heavy-chain variable regions, and single-chain antibodies, etc, comprising the same, having sufficient binding activity (affinity) with target cells, and having the ability to undergo various site-specific and uniform chemical modifications. The present invention pertains to a humanized variable region on the light-chain or heavy-chain of antibody 528 against human epidermal cell growth factor receptor 1 (Her-1), said variable region comprising the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4, wherein fragments of humanized anti-EGFR antibody lysine-substituted light-chain variable regions are formed by substituting a different amino acid for all of the lysine residues, or all of the lysine residues except for the lysine residue(s) of one specified moiety.
    Type: Grant
    Filed: July 16, 2011
    Date of Patent: September 22, 2015
    Assignee: TOHOKU UNIVERSITY
    Inventors: Izumi Kumagai, Takeshi Nakanishi, Hideaki Sanada, Ryutaro Asano, Mitsuo Umetsu
  • Publication number: 20150175713
    Abstract: Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (LH-diabody type bispecific antibody) characterized in that an L-chain is located in the N-terminal side in each polypeptide (LH type); a humanized high-functional bispecific antibody which contains said LH diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule.
    Type: Application
    Filed: January 15, 2015
    Publication date: June 25, 2015
    Applicant: TOHOKU UNIVERSITY
    Inventors: Izumi KUMAGAI, Ryutaro ASANO, Mitsuo UMETSU
  • Patent number: 8921525
    Abstract: [Problem] Disclosed is an antibody that exhibits excellent cytotoxicity and cell growth inhibition and that is based on an anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528). Further disclosed is a method for producing same, and the like. [Solution] The mutant of an H chain humanized variable region (5H) or an L chain humanized variable region (5L) of the anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528) is the aforementioned antibody characterized by having one to a plurality (for example: 1 to 5, or 1 to 3) of amino acid mutations within CDR2. Further disclosed are antibody molecules containing said region, a nucleic acid molecule coding for these polypeptides, a method for producing said antibody molecules, and the like.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: December 30, 2014
    Assignee: Tohoku University
    Inventors: Izumi Kumagai, Takeshi Nakanishi, Ryutaro Asano, Mitsuo Umetsu
  • Publication number: 20130274446
    Abstract: The purpose of the present invention is to provide fragments of humanized anti-EGFR antibody substituted-lysine light-chain or heavy-chain variable regions, and single-chain antibodies, etc, comprising the same, having sufficient binding activity (affinity) with target cells, and having the ability to undergo various site-specific and uniform chemical modifications. The present invention pertains to a humanized variable region on the light-chain or heavy-chain of antibody 528 against human epidermal cell growth factor receptor 1 (Her-1), said variable region comprising the amino acid sequence represented by SEQ ID NO: 2 or SEQ ID NO: 4, wherein fragments of humanized anti-EGFR antibody lysine-substituted light-chain variable regions are formed by substituting a different amino acid for all of the lysine residues, or all of the lysine residues except for the lysine residue(s) of one specified moiety.
    Type: Application
    Filed: July 16, 2011
    Publication date: October 17, 2013
    Applicant: TOHOKU UNIVERSITY
    Inventors: Izumi Kumagai, Takeshi Nakanishi, Hideaki Sanada, Ryutaro Asano, Mitsuo Umetsu
  • Publication number: 20130131320
    Abstract: [Problem] Disclosed is an antibody that exhibits excellent cytotoxicity and cell growth inhibition and that is based on an anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528). Further disclosed is a method for producing same, and the like. [Solution] The mutant of an H chain humanized variable region (5H) or an L chain humanized variable region (5L) of the anti-human epithelial cell growth factor receptor (1) (Her1) antibody (528) is the aforementioned antibody characterized by having one to a plurality (for example: 1 to 5, or 1 to 3) of amino acid mutations within CDR2. Further disclosed are antibody molecules containing said region, a nucleic acid molecule coding for these polypeptides, a method for producing said antibody molecules, and the like.
    Type: Application
    Filed: November 11, 2010
    Publication date: May 23, 2013
    Applicant: TOHOKU UNIVERSITY
    Inventors: Izumi Kumagai, Takeshi Nakanishi, Ryutaro Asano, Mitsuo Umetsu
  • Publication number: 20120095191
    Abstract: Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (LH-diabody type bispecific antibody) characterized in that an L-chain is located in the N-terminal side in each polypeptide (LH type); a humanized high-functional bispecific antibody which contains said LH diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule.
    Type: Application
    Filed: January 4, 2010
    Publication date: April 19, 2012
    Applicant: TOHOKU UNIVERSITY
    Inventors: Izumi Kumagai, Ryutaro Asano, Mitsuo Umetsu
  • Patent number: 7871614
    Abstract: A protein utilizing an anti-gold antibody and a gold-binding side which is a part of the anti-gold antibody is constructed. This protein is capable of specifically binding to gold. This protein or a complex protein containing such a protein can be used for the detection of a target substance.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: January 18, 2011
    Assignee: Canon Kabushiki Kaisha
    Inventors: Hidenori Shiotsuka, Takeshi Imamura, Izumi Kumagai
  • Patent number: 7855180
    Abstract: A structure comprises at least a porous body holding a substance releasably, comprising a capping member for keeping the substance inside the pore and/or on at least a part of the entire surface of the porous body, and a connecting member for connecting the porous body and the capping member separably, the connecting member comprising a biopolymer compound. A method for releasing a substance from the structure set forth comprises the steps of applying stimulation from outside to the structure, and cleaving at least one of the bonding between the connecting member and the capping member and the bonding between the connecting member and the porous member to make the substance releasable from the structure.
    Type: Grant
    Filed: March 5, 2009
    Date of Patent: December 21, 2010
    Assignee: Canon Kabushiki Kaisha
    Inventors: Hidenori Shiotsuka, Takeshi Imamura, Izumi Kumagai
  • Patent number: 7833731
    Abstract: A protein utilizing an anti-gold antibody and a gold-binding side which is a part of the anti-gold antibody is constructed. This protein is capable of specifically binding to gold. This protein or a complex protein containing such a protein can be used for the detection of a target substance.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: November 16, 2010
    Assignee: Canon Kabushiki Kaisha
    Inventors: Hidenori Shiotsuka, Takeshi Imamura, Izumi Kumagai
  • Patent number: 7807391
    Abstract: A protein utilizing an anti-gold antibody and a gold-binding side which is a part of the anti-gold antibody is constructed. This protein is capable of specifically binding to gold. This protein or a complex protein containing such a protein can be used for the detection of a target substance.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: October 5, 2010
    Assignee: Canon Kabushiki Kaisha
    Inventors: Hidenori Shiotsuka, Takeshi Imamura, Izumi Kumagai
  • Publication number: 20100173360
    Abstract: The present invention relates to a zinc oxide-binding antibody having high stability and binding activity, and high-throughput sensing technology using the antibody, such as biosensors. Specifically, the present invention relates to a peptide-grafted antibody that contains a zinc oxide-recognizing peptide in the CDR H-1 region of a camel antibody, and a solid support (e.g., a biosensor and a protein chip) containing a zinc oxide layer on which the antibody has been immobilized.
    Type: Application
    Filed: February 14, 2008
    Publication date: July 8, 2010
    Applicant: TOHOKU UNIVERSITY
    Inventors: Mitsuo Umetsu, Izumi Kumagai, Ryutaro Asano, Takeshi Nakanishi
  • Patent number: 7635475
    Abstract: The purpose of the present invention is to provide a diabody-type bispecific antibody, which is characterized by having low immunogenicity and high infiltrating activity into tumor tissues, and by being easily mass-produced at a low cost with use of microorganisms, and by being easily altered in function by means of genetic engineering. The diabody-type bispecific antibody shows a more remarkable effect than the conventional diabody-type bispecific antibodies and chemically synthesized bispecific antibodies even in a very low concentration and in the absence of the super antigen.
    Type: Grant
    Filed: August 18, 2003
    Date of Patent: December 22, 2009
    Assignee: Tohoku Techno Arch Co., Ltd.
    Inventors: Izumi Kumagai, Toshio Kudo, Kouhei Tsumoto, Ryutaro Asano
  • Publication number: 20090311806
    Abstract: A protein utilizing an anti-gold antibody and a gold-binding side which is a part of the anti-gold antibody is constructed. This protein is capable of specifically binding to gold. This protein or a complex protein containing such a protein can be used for the detection of a target substance.
    Type: Application
    Filed: May 27, 2009
    Publication date: December 17, 2009
    Applicant: CANON KABUSHIKI KAISHA
    Inventors: Hidenori Shiotsuka, Takeshi Imamura, Izumi Kumagai
  • Publication number: 20090281284
    Abstract: A protein utilizing an anti-gold antibody and a gold-binding side which is a part of the anti-gold antibody is constructed. This protein is capable of specifically binding to gold. This protein or a complex protein containing such a protein can be used for the detection of a target substance.
    Type: Application
    Filed: May 27, 2009
    Publication date: November 12, 2009
    Applicant: CANON KABUSHIKI KAISHA
    Inventors: Hidenori Shiotsuka, Takeshi Imamura, Izumi Kumagai